Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

02.06.22	Press Release: Sanofi grants Regeneron worldwide exclusive license rights to Libtayo® (cemiplimab) (GlobeNewswire)
01.06.22	Sanofi: FDA Grants Efanesoctocog Alfa Breakthrough Therapy Designation For Hemophilia A (RTTNews)
01.06.22	Press Release: FDA grants efanesoctocog alfa Breakthrough Therapy designation for hemophilia A (GlobeNewswire)
31.05.22	Regeneron : FDA Accepts Dupixent For Priority Review In Adults With Prurigo Nodularis (RTTNews)
31.05.22	Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis (GlobeNewswire)
30.05.22	Press Release: Update on Cialis® Rx-to-OTC Switch Actual Use Trial (GlobeNewswire)
27.05.22	Biotech Stocks Facing FDA Decision In June 2022 (RTTNews)
23.05.22	FDA Approves Regeneron's Dupixent To Treat Eosinophilic Esophagitis (RTTNews)
20.05.22	Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis (GlobeNewswire)
16.05.22	Sanofi : Sarclisa Combination Provides Unprecedented Median PFS In Relapsed Multiple Myeloma (RTTNews)
15.05.22	Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy (GlobeNewswire)
11.05.22	Press Release: New nirsevimab data analyses reinforce efficacy against RSV (GlobeNewswire)
04.05.22	Press Release: Foundation S: Sanofi’s new philanthropic spearhead (GlobeNewswire)
03.05.22	Press Release: Annual General Meeting of May 3, 2022 (GlobeNewswire)
28.04.22	Sanofi Q1 Profit Climbs; Backs FY22 Business EPS Growth View - Quick Facts (RTTNews)
26.04.22	Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence (GlobeNewswire)
14.04.22	Press Release: Positive Phase 1/2 study results of rilzabrutinib in people with immune thrombocytopenia published in The New England Journal of Medicine (GlobeNewswire)
07.04.22	Regeneron, Sanofi: EU Approves Dupixent For Children Aged 6 To 11 Years With Severe Asthma (RTTNews)
07.04.22	Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation (GlobeNewswire)
04.04.22	Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board (GlobeNewswire)
04.04.22	Regeneron : FDA Accepts Dupixent For Priority Review In Patients Aged 12 Yrs And Older With EoE (RTTNews)
04.04.22	Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis (GlobeNewswire)
01.04.22	Press Release: EUROAPI listing on Euronext Paris expected on May 6, 2022 (GlobeNewswire)
31.03.22	Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines (GlobeNewswire)
30.03.22	Press Release: Availability of the Q1 2022 Memorandum for modelling purposes (GlobeNewswire)
29.03.22	Press Release: Sanofi and IGM Biosciences Announce Collaboration Agreement for Oncology, Immunology and Inflammation Targets (GlobeNewswire)
29.03.22	Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver (GlobeNewswire)
28.03.22	Sanofi-aventis Reports Expanded Approval Of Dupixent In Canada To Include Children Aged Six To 11 (RTTNews)
28.03.22	Sanofi: Xenpozyme Gets Marketing Authorization In Japan For ASMD (RTTNews)
28.03.22	Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency (GlobeNewswire)
26.03.22	Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis (GlobeNewswire)
18.03.22	Press Release: Sanofi moves forward with EUROAPI listing on Euronext Paris (GlobeNewswire)
16.03.22	Seagen, Sanofi In Deal To Develop And Commercialize Multiple Novel Antibody-Drug Conjugates (RTTNews)
16.03.22	Press Release: Sanofi and Seagen announce collaboration to develop and commercialize multiple novel antibody-drug conjugates (GlobeNewswire)
15.03.22	Sanofi: Blackstone Life To Provide Investment To Advance Subcutaneous Dosage Form For Sarclisa (RTTNews)
15.03.22	Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma (GlobeNewswire)
14.03.22	Sanofi: Amcenestrant Phase 2 Trial Fails To Meet Primary Goal In ER+/HER2- Breast Cancer (RTTNews)
14.03.22	Sanofi : Phase 2 Trial Of Amcenestrant On Metastatic Breast Cancer Fails To Meet Primary Endpoint (RTTNews)
14.03.22	Sanofi provides update on Phase 2 study evaluating amcenestrant in ER+/HER2- advanced or metastatic breast cancer (GlobeNewswire)
09.03.22	Sanofi: Efanesoctocog Alfa Meets Primary, Key Secondary Endpoints In Phase 3 Study In Hemophilia A (RTTNews)
09.03.22	Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in hemophilia A, demonstrating superiority to prior factor prophylaxis treatment (GlobeNewswire)
08.03.22	Sanofi recognized by S&P as one of the most sustainability-committed companies (GlobeNewswire)
03.03.22	Nirsevimab significantly protected infants against RSV disease in Phase 3 trial (GlobeNewswire)
26.02.22	Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis (GlobeNewswire)
26.02.22	Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria (GlobeNewswire)
23.02.22	Sanofi, GSK To Seek Authorization For COVID-19 Vaccine Based On Data From Booster & Efficacy Trials (RTTNews)
23.02.22	Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine (GlobeNewswire)
22.02.22	Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors (GlobeNewswire)
18.02.22	Regeneron, Sanofi To Stop Dupixent Phase 3 Trial In Chronic Spontaneous Urticaria Due To Futility (RTTNews)
18.02.22	Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18:01		Dow Jones aktuell: Dow Jones notiert am Mittag im Plus
17:58		Handel in Europa: STOXX 50 schliesst im Minus
17:58		Schwacher Handel: SMI schliesst mit Verlusten
17:58		Verluste in Europa: Euro STOXX 50 letztendlich leichter
17:58		SPI-Handel aktuell: SPI zum Handelsende leichter
17:58		Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels
16:01		NASDAQ-Handel NASDAQ 100 schwächelt zum Start des Freitagshandels

18:01

Dow Jones aktuell: Dow Jones notiert am Mittag im Plus

17:58

Handel in Europa: STOXX 50 schliesst im Minus

17:58

Schwacher Handel: SMI schliesst mit Verlusten

17:58

Verluste in Europa: Euro STOXX 50 letztendlich leichter

17:58

SPI-Handel aktuell: SPI zum Handelsende leichter

17:58

Minuszeichen in London: FTSE 100 schwächelt zum Ende des Freitagshandels